SCHEMBL3377510

SCHEMBL3377510

COc1ccc2oc(C(=O)c3ccccc3)cc2c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.63
NPC1 O15118 6/20 0.63
KMT2A Q03164 3/20 0.63
MEN1 O00255 2/20 0.63
TSHR P16473 1/20 0.63
MAPK1 P28482 1/20 0.63
FLT3 P36888 1/20 0.61
SMN1; SMN2 Q16637 5/20 0.59
MAPT P10636 4/20 0.59
KDM4E B2RXH2 3/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
HDAC3 O15379 2/20 0.58
HDAC4 P56524 2/20 0.58
HDAC1 Q13547 2/20 0.58
HDAC7 Q8WUI4 2/20 0.58
HDAC2 Q92769 2/20 0.58
HDAC10 Q969S8 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30629240 1.00 RAB9A (0.63) RAB9ANPC1KMT2AMEN1TSHR
SCHEMBL31060243 0.88 FLT3 (0.71) FLT3MAPTKDM4EBCAT1PDGFRB
SCHEMBL1378971 0.87 ALDH1A1 (0.63) RAB9ANPC1KMT2AMEN1FLT3
SCHEMBL11112195 0.86 FLT3 (0.58) RAB9ANPC1KMT2AMEN1FLT3
SCHEMBL8761540 0.84 MAPT (0.72) RAB9ANPC1KMT2AMEN1TSHR
SCHEMBL29527237 0.83 KDM4E (0.66) FLT3KDM4EBCAT1ALDH1A1TAS1R3
SCHEMBL335319 0.83 KDM4E (0.66) FLT3KDM4EBCAT1ALDH1A1TAS1R3
SCHEMBL2033212 0.82 KDM4E (0.81) RAB9ANPC1MAPK1SMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL11498190 0.82 KDM4E (0.64) FLT3KDM4EBCAT1ALDH1A1TAS1R3
SCHEMBL5508127 0.82 MAPT (0.57) TSHRFLT3SMN1; SMN2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013114040-A1 NOVEL COMPOUNDS AND COMPOSITIONS USED AS ANTICANCER AGENTS UNIVERSITE PARIS DIDEROT - PARIS 7 (FR) 2013-08-08 WO disclosed
WO-2013114040-A1 NOVEL COMPOUNDS AND COMPOSITIONS USED AS ANTICANCER AGENTS UNIVERSITE PARIS DIDEROT - PARIS 7 (FR) 2013-08-08 WO disclosed
EP-1653944-B1 HETEROCYCLIC COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-11-10 EP disclosed
US-7696365-B2 Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-04-13 US disclosed
EP-1653944-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2006-05-10 EP disclosed
WO-2005011670-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-02-10 WO disclosed
US-20050026969-A1 Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026969-A1 Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors ACACA, ACACB, PC RAB9A 3202/4885NPC1 643/4885KMT2A 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.